U-M spin-off CytoPherx grows to 12 people

Kidney disease is one of those things you don't want to be diagnosed with. The disease has a survival rate that peaks at 30 percent and goes down quickly. University of Michigan spin-off CytoPherx hopes its new technology will reverse those numbers.

The Ann Arbor-based firm is developing new therapies for patients who suffer from acute and chronic kidney disease. It hopes to flip the current survival rates so 70 percent or more of patients with kidney disease can go onto to live fulfilling lives.

"So far the early indicators suggest we can do it," says Mark Morsfield, CFO of CytoPherx.

The nearly 3-year-old start-up employs 12 people, a couple of independent contractors and the occasional intern. The company started with three people. It is in the midst of putting its therapies through clinical trials. That process promises to bump up the staff to 18 people within the next two years as it heads toward its expected commercialization.

Source: Mark Morsfield, CFO of CytoPherx
Writer: Jon Zemke
Signup for Email Alerts

Related Company